Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA3234100
Max Phase: Preclinical
Molecular Formula: C35H40BrO5P
Molecular Weight: 571.67
Molecule Type: Small molecule
Associated Items:
ID: ALA3234100
Max Phase: Preclinical
Molecular Formula: C35H40BrO5P
Molecular Weight: 571.67
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: O=C(OCCCCCCCCCC[P+](c1ccccc1)(c1ccccc1)c1ccccc1)c1cc(O)c(O)c(O)c1.[Br-]
Standard InChI: InChI=1S/C35H39O5P.BrH/c36-32-26-28(27-33(37)34(32)38)35(39)40-24-16-5-3-1-2-4-6-17-25-41(29-18-10-7-11-19-29,30-20-12-8-13-21-30)31-22-14-9-15-23-31;/h7-15,18-23,26-27H,1-6,16-17,24-25H2,(H2-,36,37,38,39);1H
Standard InChI Key: KDIRFNXSUJACSS-UHFFFAOYSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 571.67 | Molecular Weight (Monoisotopic): 571.2608 | AlogP: 7.08 | #Rotatable Bonds: 15 |
Polar Surface Area: 86.99 | Molecular Species: NEUTRAL | HBA: 5 | HBD: 3 |
#RO5 Violations: 2 | HBA (Lipinski): 5 | HBD (Lipinski): 3 | #RO5 Violations (Lipinski): 2 |
CX Acidic pKa: 8.11 | CX Basic pKa: | CX LogP: 8.77 | CX LogD: 8.69 |
Aromatic Rings: 4 | Heavy Atoms: 41 | QED Weighted: 0.06 | Np Likeness Score: 0.28 |
1. Jara JA, Castro-Castillo V, Saavedra-Olavarría J, Peredo L, Pavanni M, Jaña F, Letelier ME, Parra E, Becker MI, Morello A, Kemmerling U, Maya JD, Ferreira J.. (2014) Antiproliferative and uncoupling effects of delocalized, lipophilic, cationic gallic acid derivatives on cancer cell lines. Validation in vivo in singenic mice., 57 (6): [PMID:24568614] [10.1021/jm500174v] |
2. CatalAn, Mabel, Castro-Castillo, Vicente, Gajardo-de la Fuente, Javier, Aguilera, Jocelyn, Ferreira, Jorge, Ramires-Fernandez, Ricardo, Olmedo, Ivonne, Molina-Berrios, Alfredo, Palominos, Charlotte, Valencia, Marcelo, Dominguez, Marta, Souto, Jose A., Jara, Jose A.. (2020) Continuous flow synthesis of lipophilic cations derived from benzoic acid as new cytotoxic chemical entities in human head and neck carcinoma cell lines, 11 (10): [PMID:33479625] [10.1039/d0md00153h] |
Source(1):